Neurocrine biosciences board of directors authorizes $500 million share repurchase program

San diego , feb. 21, 2025 /prnewswire/ -- neurocrine biosciences, inc. (nasdaq: nbix) today announced that its board of directors has authorized a new share repurchase program under which neurocrine biosciences may repurchase up to $500 million of its shares, subject to market conditions. this new share repurchase authorization is in addition to the $300 million accelerated repurchase program that was announced in october 2024 and completed in early february 2025.
NBIX Ratings Summary
NBIX Quant Ranking